Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study

References

• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
   PubMedGoogle Scholar
• Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine. 2009;27:B71–B7. doi:10.1016/j.vaccine.2009.04.070.
   PubMed Web of Science ®Google Scholar
• Harrison L, Granoff D, Pollard A. Meningococcal capsular group A, C, W, and Y conjugate vaccines. In: Orenstein WA, Offit PA, Edwards KM, Plotkin SA, editors. Vaccines. Philadelphia (PA): Elsevier; 2018. p. 619–43.
   Google Scholar
• Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313–28. doi:10.1080/14760584.2017.1258308.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018. Centers for Disease Control and Prevention. 2018.
   Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meer HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1–28.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Meningococcal disease: recommended vaccinations. European Centre for Disease Prevention and Control (ECDC). 2019.
   Google Scholar
• Knol MJ, Hahne SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, Borrow R, Ladhani SN, Ramsay ME, van der Ende A, et al. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health. 2017;2:e473–e82. doi:10.1016/S2468-2667(17)30157-3.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Sullivan E. Meningococcal vaccinations. Infect Dis Ther. 2016;5:89–112. doi:10.1007/s40121-016-0107-0.
   PubMed Web of Science ®Google Scholar
• Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J. Immunogenicity of a booster dose of quadrivalent meningococcal conjugate vaccine in previously immunized HIV-infected children and youth. J Pediatric Infect Dis Soc. 2017;6:e69–e74. doi:10.1093/jpids/piw094.
   PubMed Web of Science ®Google Scholar
• Weinberger B. Vaccines for the elderly: current use and future challenges. Immun Ageing. 2018;15:3. doi:10.1186/s12979-017-0107-2.
   PubMed Web of Science ®Google Scholar
• Yezli S. The threat of meningococcal disease during the Hajj and Umrah mass gatherings: a comprehensive review. Travel Med Infect Dis. 2018;24:51–58. doi:10.1016/j.tmaid.2018.05.003.
   PubMed Web of Science ®Google Scholar
• Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatr Infect Dis J. 2012;31:1173–83. doi:10.1097/INF.0b013e318268dfe4.
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group. Clin Diagn Lab Immunol. 1997;4:156–67. PMID: 9067649.
   PubMedGoogle Scholar
• Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. 2001;8:616–23. doi:10.1128/CDLI.8.3.616-623.2001.
   PubMedGoogle Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307–26. doi:10.1084/jem.129.6.1307.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139:e20162193. doi:10.1542/peds.2016-2193.
   PubMed Web of Science ®Google Scholar
• Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum Vaccin Immunother. 2016;12:1300–10. doi:10.1080/21645515.2015.1136040.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease — Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1018–19.
   PubMedGoogle Scholar
• Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M. Safety and immunogenicity of a booster dose of meningococcal (Groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Vaccine. 2016;34:5273–78. doi:10.1016/j.vaccine.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Timo Vesikari RB, Forsten A, Findlow H, Dhingra MS, Jordanov E. 2020. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study. Hum Vaccin Immunother. Accepted.
   PubMed Web of Science ®Google Scholar